Facing significant headwinds in its core business, Danish pharmaceutical giant Novo Nordisk is executing a costly but calculated strategic shift. The company’s management is under pressure to act as prescription numbers for key products decline and intense price competition squeezes margins. While the market focuses on these challenges in the weight-loss injection segment, Novo Nordisk is aggressively building a potential second empire in the treatment of metabolic liver disease.
A Costly Transformation Under New Leadership
The financial strain of this pivot is already materializing. The company anticipates a currency-adjusted decline in both sales and operating profit of five to 13 percent for the current year. This is driven by fierce competition from Eli Lilly and new pricing guidelines from the U.S. government. Investor sentiment reflects these pressures; the stock has lost approximately 55 percent of its value over a twelve-month period and is currently trading near its 52-week low at just over 32 euros.
Since taking the helm in July, CEO Mike Doustdar is implementing a rigorous restructuring. To achieve annual savings of around eight billion Danish kroner, the corporation is eliminating 9,000 positions and halting several development programs. The capital freed up by these cuts is being channeled directly into new growth areas.
The Billion-Dollar Acquisition Filling a Critical Gap
The central challenge lies in the established GLP-1 business. To reduce this dependency, Novo Nordisk is making substantial investments in treating MASH, a chronic and potentially life-threatening liver condition. In December 2025, the group finalized the acquisition of Akero Therapeutics for up to 5.2 billion U.S. dollars. This deal alone is projected to reduce operating profit growth in 2026 by three percentage points.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The primary asset gained is the drug candidate Efruxifermin (EFX), currently in a pivotal Phase 3 trial targeting patients with advanced liver cirrhosis (Stage F4). This move has clear strategic logic. Although Novo Nordisk’s well-known drug Wegovy has already received FDA approval for MASH treatment, it only covers earlier stages of liver fibrosis (F2 and F3). EFX provides the potential to treat the full spectrum of the disease. With over 80% of MASH patients being overweight, this new field integrates seamlessly with the company’s existing metabolic expertise.
A Crowded Competitive Landscape
The race to dominate this new market is intensifying. Pharmaceutical giants including GSK and Roche have invested billions in MASH developers in recent months. Furthermore, Madrigal Pharmaceuticals has already brought the first specific drug for this indication to market, setting a competitive benchmark.
Recent data updates from mid-March 2026 highlight the rapid pace at which Novo Nordisk is advancing its pipeline beyond weight-loss injections. The company’s ability to maintain its dominance in the metabolic segment now hinges significantly on the clinical outcomes of the SYNCHRONY program. These Phase 3 results will determine whether the 5.2-billion-dollar wager on EFX secures the hoped-for market approval for severe liver damage and successfully compensates for the declining GLP-1 revenues.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from March 19 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 19.
Novo Nordisk: Buy or sell? Read more here...
